(formatting) |
(formatting) |
||
| Line 801: | Line 801: | ||
<br> | <br> | ||
= | ='''Movement Disorders (not diagnosis specific)'''= <!--T:183--> | ||
===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149916/ Role for the nicotinic cholinergic system in movement disorders; therapeutic implications]=== <!--T:184--> | ===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149916/ Role for the nicotinic cholinergic system in movement disorders; therapeutic implications]=== <!--T:184--> | ||
| Line 812: | Line 811: | ||
*Citation: Quik M, Zhang D, Perez XA, Bordia T. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther. 2014 Oct;144(1):50-9. doi: 10.1016/j.pharmthera.2014.05.004. Epub 2014 May 14. PMID: 24836728; PMCID: PMC4149916. | *Citation: Quik M, Zhang D, Perez XA, Bordia T. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther. 2014 Oct;144(1):50-9. doi: 10.1016/j.pharmthera.2014.05.004. Epub 2014 May 14. PMID: 24836728; PMCID: PMC4149916. | ||
*Acknowledgements: This work was supported by grants NS59910 and NS 65851 from the National Institutes of Health. | *Acknowledgements: This work was supported by grants NS59910 and NS 65851 from the National Institutes of Health. | ||
<br> | |||
==Multiple Sclerosis - Humans / Experimental Autoimmune Encephalomyelitis (EAE) - Animals== <!--T:186--> | ==Multiple Sclerosis - Humans / Experimental Autoimmune Encephalomyelitis (EAE) - Animals== <!--T:186--> | ||
edits